

## Product Data Sheet

## (Leu31,Pro34)-Peptide YY (human)

Cat. No.:	HY-P3877	
CAS No.:	179986-95-9	
Molecular Formula:	C <sub>195</sub> H <sub>296</sub> N <sub>54</sub> O <sub>56</sub>	
Molecular Weight:	4292.75	
Sequence:	Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr -Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Leu-Thr-Arg-Pro-Arg-Tyr-NH2	
Sequence Shortening:	YPIKPEAPGEDASPEELNRYYASLRHYLNLLTRPRY-NH2	
Target:	Neuropeptide Y Receptor	
Pathway:	GPCR/G Protein; Neuronal Signaling	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

BIOLOGICAL ACTIVITY			
Description	(Leu31,Pro34)-Peptide YY (human) is a Peptide YY (HY-P1514) derivative and is a potent and selective Y <sub>1</sub> agonist with a K <sub>D</sub> of 1.0 nM <sup>[1]</sup> .		
IC <sub>50</sub> & Target	NPY Y <sub>1</sub> receptor 1.0 nM (Kd)	NPY Y <sub>2</sub> receptor 670 nM (Kd)	
In Vitro	(Leu31,Pro34)-Peptide YY demonstrates high (nM) affinity in rat frontoparietal cortical membrane preparations (Y <sub>1</sub> -enriched tissue) and the rabbit saphenous vein (Y <sub>1</sub> in vitro bioassay) but only low affinity in a Y <sub>2</sub> -enriched preparation (rat hippocampus) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	(Leu31,Pro34)-Peptide YY (0.1- MCE has not independently co Animal Model: Dosage:	-1 nmol/day; ICV; 14 days) displays anxiolytic and antidepressant effect in rats <sup>[2]</sup> . onfirmed the accuracy of these methods. They are for reference only. Male Sprague Dawley rats weighing 150-170 g, OBX/Sham model <sup>[2]</sup> 0.1, 0.3 and 1 nmol/day	
	Administration:	ICV, for 14 days	
	Result:	Significantly decreased hyperlocomotion and immobility time in OBX animals. Reversed the deficit in social contacts in OBX animals. Reduced grooming behavior in sham animals.	

## REFERENCES

[1]. Dumont Y, et al. Peptide YY derivatives as selective neuropeptide Y/peptide YY Y1 and Y2 agonists devoided of activity for the Y3 receptor sub-type. Brain Res Mol Brain Res. 1994 Oct;26(1-2):320-4.

[2]. Morales-Medina JC, et al. Role of neuropeptide Y Y<sub>1</sub> and Y<sub>2</sub> receptors on behavioral despair in a rat model of depression with co-morbid anxiety. Neuropharmacology. 2012 Jan;62(1):200-8.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA